Are you ready for Butalbital/APAP combination products to become a Controlled Substance? Written-by: Deneen Fumich, RPh On April 12, 2022, the Drug Enforcement Administration “DEA” published in the Federal Register a Notice of Proposed Rulemaking. The DEA proposed to...
FDA Proposed Rules Review, Part 3 of 4: WDD Licensing Standards & Approved Organizations Oversight Written-by: Sumeet Singh, CEO In this third part of the review of FDA’s proposed rules, we focus on the national standards FDA seeks to levy on Wholesale Drug...
Nevada to Require Nonresident Pharmacists To Obtain Licensure Written-by: Deneen Fumich, RPh Nevada Reinterpreted NRS 639.100(1)(a) to Require Nonresident Pharmacist Licensure Late last year, Nevada reinterpreted its enforcement of NRS 639.100(1)(a) to require...
Puerto Rico Product Registration: Undocumented Rule and Enforcement Change Written-by: Deneen Fumich, RPh Understanding Registration Basics Pursuant to Puerto Rico Chapter 5, Article 5.01 Manufacturing, Distribution and Dispensing of Drugs, each pharmaceutical...
3 The Complexities and Application of Drug Takeback Programs Written-by: Deneen Fumich, RPh Pre-Article Comment: For those Health Care Practitioners and Pharmacies that are not located in any of the jurisdictions with a Producer/Manufacturer Funded Drug Takeback...
